Modality
Multispecific
MOA
GLP-1ag
Target
RET
Pathway
Neuroinflam
FLSchizophreniaUC
Development Pipeline
Preclinical
~Apr 2011
→ ~Jul 2012
Phase 1
~Oct 2012
→ ~Jan 2014
Phase 2
~Apr 2014
→ ~Jul 2015
Phase 3
~Oct 2015
→ ~Jan 2017
NDA/BLA
Apr 2017
→ Nov 2031
NDA/BLACurrent
NCT07987434
1,494 pts·Schizophrenia
2018-10→2031-11·Terminated
NCT06133310
1,453 pts·UC
2017-04→2026-08·Terminated
2,947 total pts2 indications
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-08-225mo awayPh3 Readout· UC
2031-11-215.6y awayPh3 Readout· Schizophrenia
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
NDA/BLA
Termina…
NDA/BLA
Termina…
Catalysts
Ph3 Readout
2026-08-22 · 5mo away
UC
Ph3 Readout
2031-11-21 · 5.6y away
Schizophrenia
Terminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07987434 | NDA/BLA | Schizophrenia | Terminated | 1494 | NT-proBNP |
| NCT06133310 | NDA/BLA | UC | Terminated | 1453 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | CD19 | |
| RHH-5389 | Roche | Preclinical | RET | |
| Fixanesiran | AbbVie | Preclinical | RET | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 | |
| VRT-1576 | Vertex Pharma | Phase 2/3 | RET | |
| MRN-7601 | Moderna | Phase 2 | IL-13 | |
| ARG-3458 | Argenx | Preclinical | RET | |
| ARG-1250 | Argenx | Phase 2 | C5 | |
| ILM-5680 | Illumina | Phase 2 | BET |